Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity

About this episode

Tao Zhu MD discusses the promising results of the investigational drug QLS5132 for patients with advanced platinum-resistant ovarian cancer at AACR 2026.

Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity An interview with: Tao Zhu, MD, Chief Physician and Vice President, Zhejiang Cancer Hospital, China SAN DIEGO, USA— The investigational drug QLS5132 had “remarkable anti-tumor activity” in patients with late-stage platinum resistant ovarian cancer, according to data reported at the American Association of Cancer Research 2026 Annual Meeting. The drug is an antibody drug conjugate targeting the transmembrane protein claudin 6, which has almost no expression in healthy tissue, but is expressed in some cancer tissues, including ovarian cancer. Tao Zhu MD, chief physician and vice president of Zhejiang Cancer Hospital in China told the AACR about the encouraging response rates they noted among 28 patients with ovarian cancer, with manageable toxicities. He gave more details to our reporter, Peter Goodwin: AUDIO JOURNAL OF ONCOLOGY: Tao Zhu MD IN: [GOODWIN]”I am at the AACR Meeting … OUT: ….for the Audio Journal of Oncology 4:49 AACR 2026 ABSTRACT: Presentation CT037: Publishing Title: A first-in-human phase 1 trial of a novel claudin 6…

People in this episode

Host: Peter Goodwin

Guest: Tao Zhu MD

Topics covered

• Ovarian Cancer
• Antibody Drug Conjugate
• Clinical Trials
• Cancer Research
• Platinum-Resistant Cancer
• Toxicity Management

Keywords

• Anti-Claudin 6
• Ovarian Cancer
• QLS5132
• AACR 2026
• Antibody Drug Conjugate
• Platinum-Resistant
• Toxicity
• Clinical Trials

Mentioned in this episode

Organizations: Zhejiang Cancer Hospital, American Association of Cancer Research

Products: QLS5132

More episodes of Audio Journal of Oncology Podcast

• Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer · May 6, 2026 · 8 min
• Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer · April 30, 2026 · 11 min
• Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life · April 27, 2026 · 10 min
• Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy · April 24, 2026 · 8 min
• Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors · April 23, 2026 · 9 min
• Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings · April 16, 2026 · 5 min